Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 25, 2019updated 23 Dec 2019 8:27am

Takeda’s maribavir shows promise in Phase II CMV infection study

Takeda Pharmaceutical has reported positive data from the Phase II clinical trial of its antiviral drug candidate maribavir (TAK-620) in cytomegalovirus (CMV) infection following hematopoietic cell or solid organ transplant.

Takeda Pharmaceutical has reported positive data from the Phase II clinical trial of its antiviral drug candidate maribavir (TAK-620) in cytomegalovirus (CMV) infection following hematopoietic cell or solid organ transplant.

Maribavir acts on a specific protein of the virus, UL97 protein kinase, to potentially inhibit viral DNA replication and encapsidation. The mechanism is also expected to prevent viral capsids from escaping the nucleus of infected cells.

The randomised, open-label Phase II trial compared the safety and tolerability of 400mg, 800mg and 1,200mg maribavir to 900mg valganciclovir in 159 adult patients over 12 weeks.

The primary efficacy endpoint of the trial was the proportion of responsive participants having undetectable plasma CMV DNA.

Data showed that 62% of patients on Takeda’s drug experienced a treatment effect within three weeks of therapy compared to 56% of those who received valganciclovir.

At six weeks, the response rates were observed to be 79% versus 67%.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Based on the findings, Takeda said that maribavir showed antiviral activity against CMV infection and led to a decrease in actively multiplying virus in the blood, after hematopoietic cell or solid organ transplant.

According to safety and tolerability data, 67% of subjects across maribavir arms had at least one treatment-emergent adverse event (TEAE), compared to 22% on valganciclovir.

Takeda Pharmaceutical Rare Diseases therapeutic area unit head Daniel Curran said: “Based on these results, we are evaluating maribavir for the treatment of post-transplant CMV infection in two global Phase III trials.

“The continued development of maribavir reflects the progress of our late-stage rare disease pipeline and our commitment to delivering innovative medicines for patients who have diseases like CMV where there are significant unmet needs.”

Enrolment is ongoing for the two Phase III trials of the drug to treat CMV infection in transplant patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU